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The job of the immune system is to respond to signals
released by tissues that are being destroyed by foreign invaders,
such as viruses and bacteria, and to destroy the invaders. These
signals have been termed “danger” signals (1). Destruction of
tissues by uncontrolled cell growth characteristic of cancer is
expected to also generate danger signals, albeit possibly
qualitatively different due to the absence of infectious
agents. Evidence that the immune system not only detects
the presence of cancer but also destroys it and remembers it
through the recognition of tumor-specific antigens was
provided in the late 1950’s (2) and has been confirmed
many times in increasingly more sophisticated animal models
and in cancer patients. What has not been fully accepted,
however, in part because supporting data are only now
emerging, is that the immune system can recognize precursors
of cancer and in most instances destroy them before they
become clinically apparent. This concept termed “immune
surveillance” has had as many proponents as opponents, the
debate being fueled by reasoned arguments rather than experi-
mental data. In recent years, this has begun to change. Studies
in animal models and in certain human diseases are providing
evidence that the immune system monitors and modulates
tumor growth (3, 4). As the report by Dhodapkar et al. (5) in
this issue illustrates, one way to document cancer surveillance
by the human immune system could be to analyze immune
responses against a premalignant disease, precursor to cancer.
 
A Fresh Look at Cancer Immunosurveillance.
 
If the immune
system is involved in protection from tumor growth, then
immunodeficient animals should develop tumors more fre-
quently. Schreiber and colleagues tested this hypothesis and
found that, indeed, mice lacking lymphocytes or deficient in
 
IFN signaling (RAG2
 
 
 
/
 
 
 
 mice and STAT1
 
 
 
/
 
 
 
 mice, respec-
tively) develop spontaneous tumors and are more susceptible
to carcinogen-induced tumors than WT mice (3). Further-
more, they have shown that tumors grown in immuno-
competent mice are much less aggressive and often express
different antigens to those from immunodeficient mice.
This influence of the immune system on the nature of the
tumor has been termed “cancer immunoediting.”
Support for cancer immunoediting in humans comes
from highly reproducible findings of tumor-specific cellular
and humoral immune responses in patients with cancer,
concomitant with loss of either the antigens or the presenting
HLA molecules on the tumor cells (6). However, proof
that these immune responses actually alter the course of disease
in people is more difficult to find. Evidence has been
sought in patients with paraneoplastic neurologic degeneration
(7). These patients present initially with neurologic problems,
but after a more thorough examination they are found to
harbor small adenocarcinomas. These tumors, which are
most frequently breast, ovarian, or lung cancers, express
defined neuronal antigens, and the patients produce high
titer antibodies and a high frequency of cytotoxic T cells
against these antigens. This immunity, which is destructive
to neuronal tissue, appears to have been generated in response
to the tumor and to be suppressing the growth of the tumor
(8). In general, tumors in these patients are very small, not
metastatic, and often extensively infiltrated with lymphocytes.
They have also been known to spontaneously regress.
These rare windows of opportunity to witness effective
antitumor immunity in humans suggest that it should be
possible to use cancer vaccines to generate protective tumor-
specific immunity (9, 10).
 
Moving Toward Premalignancy Vaccines.
 
Despite our exten-
sive knowledge of antitumor immune effector mechanisms
and the long list of well-defined tumor antigens (11), attempts
to elicit or boost effective immune responses in patients
who have clinically evident cancer (therapeutic vaccines)
have had very limited success (9). Although it is almost certain
that the vaccines tested could be improved further, the
greatest barriers to success have been the immunosuppressed
status of cancer patients and the many immune evasion
mechanisms acquired by tumors as they progress from an
early preneoplastic lesion to a fully malignant cancer (6).
Even if we can elicit more robust immune responses in
cancer patients, the immune evasion mechanisms will be
hard to overcome.
To take advantage of the strengths of the immune response
(its specificity, multiple effector functions, and memory)
while recognizing its weaknesses (that it is slow to develop
and ineffective against established tumors), we must change
the target of antitumor vaccines. Until now, tumor immu-
nologists have focused on antigens expressed on tumor
cells. However, cancer geneticists, molecular biologists,
and pathologists have provided a better understanding of
the process of tumorigenesis, and for several human cancers
the premalignant states have been defined (12–16). It appears
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that these early steps in the process do not escape the atten-
tion of the immune system.
 
Immune Response Against Premalignancy.
 
In this issue,
Dhodapkar et al. (5) focus on patients with preneoplastic
gammopathy (MGUS), a clonal expansion of transformed
plasma cells that is a direct precursor of multiple myelomas
(17). Many of these patients do not progress to myelomas.
The authors postulated that the lack of progression might
be due in part to immune surveillance. They found that
MGUS patients had effector CD8
 
 
 
 T cells that responded
in vitro to DCs that had taken up and processed the pre-
neoplastic plasma cells. In contrast, in myeloma patients T
cells must be expanded for 1–2 wk in culture before tu-
mor-specific T cell responses can be detected (18). MGUS-
specific T cells reside in the BM, also the residence of the
preneoplastic plasma cells. The exact mechanism of control
of tumor progression by MGUS-specific T cells is not
known. The T cells produce IFN-
 
 
 
, and thus, in addition
to directly eliminating the preneoplastic cells they can po-
tentially modulate the IFN-
 
 
 
 responsive STAT-3 and IL-6
signaling important for myeloma growth (19, 20). IFN-
 
 
 
can also inhibit angiogenesis and osteoclastogenesis, which
are features of multiple myelomas but not of MGUS (21).
The target antigens recognized by MGUS-specific T cells
were not expressed on one multiple myeloma cell line that
was tested. If this holds true for other myeloma cell lines, it
would imply that full transformation to myeloma might be a
result of mutations that allow escape from T cell immunity.
Alternatively, the inability of the immune response to fully
eliminate the preneoplastic clone may in some cases lead to
exhaustion or deletion of MGUS-specific T cells and allow
development of myelomas. Although the frequency of
MGUS-specific T cells was more than 50 times higher than
myeloma-specific T cells, this frequency (55/10
 
5
 
) may still
be too low to completely eliminate the preneoplastic clone.
One is tempted to postulate that boosting the frequency 10-
fold or more by vaccination could result in a complete elim-
ination of preneoplastic cells.
Identification of immunogenic antigens on preneoplastic
cells provides an unprecedented opportunity to prepare the
immune system through vaccination for the elimination of
transformed cells at their earliest manifestation. Thus, fu-
ture efforts should be focused on identifying antigens that
are differentially expressed between normal cells and pre-
neoplastic cells. Several mouse models of human cancer ex-
ist in which tumors develop early in life and undergo step-
wise progression similar to the human cancer (10, 22).
Others are in the process of being created either using
transgenic or gene knockout approaches. These models
will be useful in documenting the effectiveness of the im-
mune system to control tumor formation and progression
and its specificity in eliminating abnormal cells while spar-
ing normal tissue. Several tumor antigens that have been
well characterized for their tumor-specific expression and
immunogenicity are already known to be expressed in pre-
neoplastic precursor lesions. They are ready to be tested in
vitro and in animal models for their ability to protect
against incipient tumors.
 
MUC1.
 
Epithelial mucin MUC1 was the first human
tumor antigen to be reported as a target for human cyto-
toxic T cells (23). Moreover, it was the first example of a
tumor antigen recognized by T cells that is shared by differ-
ent tumors, such as breast, colon, pancreas, ovary, lung, and
multiple myelomas. Expression of MUC1 on normal tissues
is usually at a much lower level and characterized by a dif-
ferent repertoire of immune epitopes. Some of the epitopes
are exquisitely tumor specific, owing in part to differential
glycosylation in normal and tumor cells (24). Tumor forms
of MUC1 and other mucins are also expressed in many pre-
neoplastic lesions, such as pancreatic intraepithelial neopla-
sia, which are precursors of pancreatic cancer (12), and ade-
nomatous polyps, which are precursors of colon cancer (25).
Considering that MUC1 is also expressed on multiple my-
eloma, the report by Dhodapkar et al. (5) begs the question
whether MUC1-specific T cells can be detected in MGUS
patients. We have shown recently that some patients who
have had adenomatous polyps removed have high levels of
antibody against MUC1 (26). Importantly, this antibody is
of the IgG isotype, suggesting the involvement of helper
T cells. In contrast, patients with colon cancer have low
levels of anti-MUC1 antibodies of the IgM isotype, indicat-
ing the lack of T cell help (27). 
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Vaccination against tumor-specific epitopes on MUC1
protects mice from a MUC1
 
 
 
 tumor challenge (28). A
good mouse model of spontaneous pancreatic cancer has
been developed in which the potential of MUC1-specific
immunity to eliminate preneoplastic lesions and prevent
tumor progression can be studied (22). Early in life, these
mice exhibit dysplasia in the pancreas that progress to mi-
croadenomas and then to fully transformed MUC1
 
 
 
 pan-
creatic adenocarcinomas. This process is accompanied by
appearance at 
 
 
 
15 wk of age of low frequency MUC1-
specific CD8
 
 
 
 T cells that disappear as the tumor progresses
(29). However, when expanded in vitro and adoptively
transferred in large numbers, these T cells can prevent
growth of a transplanted tumor (30). These results suggest
that inducing a robust anti-MUC1 response before tumor
occurrence could serve to prevent development and pro-
gression of pancreatic cancer.
 
Cyclin B1.
 
Another shared tumor antigen shown re-
cently to be recognized by both human antibodies and T
cells is cyclin B1 (31). Tumors of various types, leukemias,
lymphomas, and epithelial adenocarcinomas were found to
overexpress cyclin B1 protein in the cytoplasm, and cyclin
B1–derived peptides were presented in the context of
HLA–class I and class II molecules. Patients with cyclin B1–
overexpressing tumors have circulating cyclin B1–specific
CD8
 
 
 
 T cells and several different isotypes of anti–cyclin
B1 antibody. As in the case of anti-MUC1 responses, the T
cell frequency is low, as is the antibody titer. Cyclin B1
overexpression is a result of inactivation of p53 function
(32). Thus, all tumors that have either mutated or deleted
p53 can be targets of anti–cyclin B1 immunity. P53 muta-
tions are early events in the carcinogenesis of many tumors
and are found with high frequency in premalignant lesions
(33, 34). This makes early lesions especially good targets for
cyclin B1–specific immune responses. For example, many
lung cancers overexpress cyclin B1 and those that do have a
much more aggressive phenotype (35). Robust cyclin B1–
specific immunity would be desirable to change the course
of these cancers, but generating robust immunity in lung
cancer patients, as in all other cancer patients, is likely to be
very difficult. Premalignant lesions in the lung are character-
ized by p53 mutations (36), which would be expected to
lead to cyclin B1 overexpression. There is currently no
treatment for individuals with preneoplastic lung disease.
These individuals would be ideal candidates for prophylactic
vaccines, and cyclin B1 is one potential candidate antigen.
 
Change in Direction.
 
In addition to MUC1 and cyclin
B1, there are many other tumor antigens that are being
tested as components of therapeutic cancer vaccines, which
may also be expressed in premalignancy and could be po-
tentially much more effective in the prophylactic setting. In
parallel with screening of the known tumor antigens for
their expression in premalignant disease, effort and re-
sources need to be invested in the search for new antigens
that characterize preneoplastic disease and in the develop-
ment of animal models in which their potential to prevent
cancer can be tested. The tremendous effort that has gone
 
into tumor antigen discovery in the last 15 yr has yielded
many candidate antigens that can be used in prophylactic
vaccines. More importantly, it has established numerous
experimental methods that can now be applied to antigen
discovery in premalignant disease.
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